Loading...
•
Mar 31, 2021
Fulcrum Therapeutics Q1 2021 Earnings Report
Reported first quarter 2021 financial results and business highlights.
Key Takeaways
Fulcrum Therapeutics reported a net loss of $17.0 million for the first quarter of 2021, with collaboration revenues of $4.8 million. The company's cash, cash equivalents, and marketable securities were $143.9 million as of March 31, 2021, which is expected to fund operations into the fourth quarter of 2022.
On track to present data from Phase 2b ReDUX4 trial with losmapimod in FSHD at virtual FSHD International Research Congress in June 2021.
On track to report data from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021.
Advanced FulcrumSeek discovery efforts and strategic collaborations with Acceleron and MyoKardia.
Christopher Morabito, M.D. has been appointed Chief Medical Officer, effective May 10, 2021.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
The company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2022.